Back to top
more

Universal Health Services (UHS)

(Delayed Data from NYSE)

$205.26 USD

205.26
632,500

+0.95 (0.46%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $205.49 +0.23 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 11% (28 out of 250)

Industry: Medical - Hospital

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Smith & Nephew's (SNN) 5% Stake Acquired by Cevian Capital

by Zacks Equity Research

Smith & Nephew (SNN) eyes future growth as Cevian Capital purchases a 5% stake in the company.

Microbot Medical (MBOT) Inks Agreement to Begin LIBERTY Trial

by Zacks Equity Research

Microbot Medical's (MBOT) LIBERTY Endovascular Robotic System trial expands to Baptist Hospital of Miami, promising advancements in clinical outcomes and endovascular procedures.

Lucid Diagnostics (LUCD) Reports Positive ESOGUARD BE-1 Data

by Zacks Equity Research

Lucid Diagnostic's (LUCD) ESOGUARD BE-1 study data shows high sensitivity and negative predictive value for the EsoGuard test, enhancing early detection of esophageal precancer in a screening population.

Here's Why You Should Add DaVita (DVA) to Your Portfolio Now

by Zacks Equity Research

DaVita's (DVA) strength in its kidney care segment raises optimism about the stock.

KORU Medical's (KRMD) FreedomEdge Gets Regulatory Nod in Japan

by Zacks Equity Research

KORU Medical (KRMD) announces the receipt of regulatory clearance for its FreedomEdge System in Japan.

IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod

by Zacks Equity Research

IceCure Medical's (ICCM) XSense Cryoablation System receives FDA approval, marking a pivotal step in minimally-invasive tumor treatment across multiple medical fields

Reasons to Retain Revvity (RVTY) Stock in Your Portfolio Now

by Zacks Equity Research

Revvity's (RVTY) strong product portfolio raises optimism about the stock.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Avantor (AVTR) Launches Solutions for Gene Therapy Harvest

by Zacks Equity Research

Avantor's (AVTR) solutions are intended to provide gene therapy manufacturers with sustainable and efficient alternatives to traditional methods, thus improving viral particle harvest and quality

Masimo's (MASI) WI Sport Wearable Gets a New Powerful Feature

by Zacks Equity Research

Masimo (MASI) announces Sleep Halo, a new feature for its Masimo W1 Sport advanced health tracking wearable.

GE Healthcare (GEHC) Enters Partnership to Boost MRI Technology

by Zacks Equity Research

GE Healthcare's (GEHC) alliance is likely to establish an Innovative MRI Research and Development center to advance MRI innovation and patient care

Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now

by Zacks Equity Research

PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.

PacBio (PACB) and Form Bio to Boost AAV Industry Development

by Zacks Equity Research

PacBio (PACB) and Form Bio collaborate to form an expert AAV Working Group to introduce essential tools for AAV development and research professionals.

Zacks Value Trader Highlights: BASF, Ford Motor, KB Home, PVH and Universal Health Services

by Zacks Equity Research

BASF, Ford Motor, KB Home, PVH and Universal Health Services are part of the Zacks Value Trader blog.

Tracey Ryniec headshot

5 Top Ranked Classic Value Stocks for June 2024

by Tracey Ryniec

With major indexes hitting new all-time highs, are there any classic value stocks left?

Masimo (MASI), Cleveland Clinic Unite to Enhance Patient Care

by Zacks Equity Research

Masimo (MASI) collaborates with Cleveland Clinic to boost patient care by combining its Hospital Automation platform with the latter's central patient monitoring platforms.

Community Health (CYH) & Cost Plus Drugs Expand Collaboration

by Zacks Equity Research

Community Health (CYH) is now set to source drugs from the Cost Plus Drugs Marketplace under the new expanded partnership.

Zacks.com featured highlights The Gap, Universal Health Services and Inter

by Zacks Equity Research

The Gap, Universal Health Services and Inter have been highlighted in this Screen of The Week article.

Zacks Investment Ideas feature highlights: Tenet Healthcare and United Health Services

by Zacks Equity Research

Tenet Healthcare and United Health Services have been highlighted in this Investment Ideas article.

Bryan Hayes headshot

Top Health Care Stocks Beating the S&P 500 This Year

by Bryan Hayes

The health care space contains several market leaders that are widely outperforming.

BD's (BDX) New Research Tool to Aid Single-Cell Analysis

by Zacks Equity Research

BD (BDX) announces the commercial launch of its new single-cell research tool, BD Rhapsody ATAC-Seq Assay, to help researchers understand DNA regulation.

Swayta Shah headshot

3 Stocks With Upgraded Broker Ratings to Buy for Robust Returns

by Swayta Shah

Brokers have deeper insights into stocks and macroeconomic factors. So, one should follow broker rating upgrades to pick stocks like Gap Inc. (GPS), Universal Health (UHS) and Inter & Co (INTR).

Ekso Bionics' (EKSO) New Partnership to Aid Its Ekso Devices

by Zacks Equity Research

Ekso Bionics (EKSO) announces a research partnership with Shepherd Center to create training and research programs for the Ekso devices.

Here's Why You Should Retain HealthEquity (HQY) Stock for Now

by Zacks Equity Research

HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.